Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%
Ph early_phase_1
1
17%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 13 (50.0%)
Phase 22 (33.3%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedearly_phase_1

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

NCT00437086
terminatedphase_1

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

NCT00361088
completedphase_2

PS-341 in Treating Patients With Metastatic Kidney Cancer

NCT00025376
completedphase_2

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

NCT00054665
completedphase_1

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

NCT00237627
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00437086Early Phase 1

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Completed
NCT00361088Phase 1

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

Terminated
NCT00025376Phase 2

PS-341 in Treating Patients With Metastatic Kidney Cancer

Completed
NCT00054665Phase 2

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed
NCT00237627Phase 1

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Completed
NCT00083460Phase 1

Study of Combination PS-341 and Thalidomide in Multiple Myeloma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6